17555-51-0

Usage

Type

Semisynthetic derivative of rifamycin S

Source

Derived from rifamycin S, an antibiotic produced by Amycolatopsis mediterranei bacterium

Classification

Rifamycin antibiotic

Mechanism of Action

Binds to the beta subunit of bacterial DNA-dependent RNA polymerase

Mode of Inhibition

Inhibits the transcription process

Antibacterial Activity

Potent antibacterial agent

Target Bacteria

Particularly effective against Gram-positive bacteria

Spectrum of Activity

Effective against various bacterial infections

Therapeutic Potential

Valuable component in the treatment of bacterial infections

Additional Therapeutic Applications

Potential treatment for tuberculosis and other mycobacterial infections

InChI:InChI=1/C35H43NO11/c1-15-10-9-11-16(2)34(44)36-21-14-22(37)24-25(31(21)42)30(41)20(6)32-26(24)33(43)35(7,47-32)46-13-12-23(45-8)17(3)28(39)19(5)29(40)18(4)27(15)38/h9-15,17-19,23,27-29,38-41H,1-8H3,(H,36,44)/b10-9+,13-12+,16-11+

Upstream product

• 62623-68-1 rifamycin S 
• 67-64-1 acetone 

Downstream Products

• 51757-21-2 O²³,O²⁵-isopropylidene-21-oxo-O²⁵-deacetyl-O¹,O⁴-didehydro-21-deoxy-rifamycin 
• 51757-16-5 O²³,O²⁵-isopropylidene-O²⁵-deacetyl-O¹,O⁴-didehydro-rifamycin 

Relevant academic research and scientific papers

DRUGS WITH ANTICHOLESTATIC ACTIVITY

New compounds belonging to the structural formula (I) are described. in which R1, R2, A, Y and X are specified in the description, useful in the treatment of cholestasis and substantially devoid of antibacterial activity. The synthesis process of said compounds, the pharmaceutical compositions containing them and their use in therapy are also described.

NEW DRUGS WITH ANTICHOLESTATIC ACTIVITY

New compounds belonging to the structural formula (I) are described. formula (I) in which R1, R2, A, Y and X are specified in the description, useful in the treatment of cholestasis and substantially devoid of antibacterial activity. The synthesis process of said compounds, the pharmaceutical compositions containing them and their use in therapy are also described.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.